Suppr超能文献

囊性纤维化患者的抗菌治疗

Antimicrobial Treatment of in Patients With Cystic Fibrosis.

作者信息

Esposito Susanna, Pennoni Guido, Mencarini Valeria, Palladino Nicola, Peccini Laura, Principi Nicola

机构信息

Pediatric Clinic, Cystic Fibrosis Center of Umbria Region, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, Italy.

Pediatric Unit, Cystic Fibrosis Center of Umbria Region, Branca Hospital, Branca, Italy.

出版信息

Front Pharmacol. 2019 Aug 7;10:849. doi: 10.3389/fphar.2019.00849. eCollection 2019.

Abstract

is a ubiquitous human commensal pathogen. It is commonly isolated in cystic fibrosis (CF) patients and is considered one of the main causes of the recurrent acute pulmonary infections and progressive decline in lung function that characterize this inherited life-threatening multisystem disorder. However, the true role of in CF patients is not completely understood. The main aim of this narrative review is to discuss the present knowledge of the role of in CF patients. Literature review showed that despite the fact that the availability and use of drugs effective against have coincided with a significant improvement in the prognosis of lung disease in CF patients, clearly evidencing the importance of therapy, how to use old and new drugs to obtain the maximal effectiveness has not been precisely defined. The most important problem remains that the high frequency with which is carried in healthy subjects prevents the differentiation of simple colonization from infection. Moreover, although experts recommend antibiotic administration in CF patients with symptoms and in those with persistent detection of , the best antibiotic approach has not been defined. All these problems are complicated by the evidence that the most effective antibiotic against methicillin-resistant (MRSA) cannot be used in patients with CF with the same schedules used in patients without CF. Further studies are needed to solve these problems and to assure CF patients the highest level of care.

摘要

是一种普遍存在的人体共生病原体。它在囊性纤维化(CF)患者中常被分离出来,被认为是这种遗传性危及生命的多系统疾病所特有的反复急性肺部感染和肺功能进行性下降的主要原因之一。然而,其在CF患者中的真正作用尚未完全明确。本叙述性综述的主要目的是讨论目前关于其在CF患者中作用的认识。文献综述表明,尽管有效对抗它的药物的可获得性和使用与CF患者肺部疾病预后的显著改善同时出现,清楚地证明了针对它治疗的重要性,但如何使用新旧药物以获得最大疗效尚未得到精确界定。最重要的问题仍然是健康受试者中它的携带频率很高,这使得难以区分单纯定植与感染。此外,尽管专家建议对有症状的CF患者以及持续检测到它的患者使用抗生素,但最佳的抗生素使用方法尚未确定。所有这些问题因以下证据而变得复杂:针对耐甲氧西林(MRSA)最有效的抗生素不能以与非CF患者相同的方案用于CF患者。需要进一步研究来解决这些问题,并确保CF患者获得最高水平的护理。

相似文献

1
Antimicrobial Treatment of in Patients With Cystic Fibrosis.囊性纤维化患者的抗菌治疗
Front Pharmacol. 2019 Aug 7;10:849. doi: 10.3389/fphar.2019.00849. eCollection 2019.

引用本文的文献

本文引用的文献

8
Dalbavancin in the treatment of different gram-positive infections: a real-life experience.达巴万星治疗不同革兰阳性感染:真实世界经验。
Int J Antimicrob Agents. 2018 Apr;51(4):571-577. doi: 10.1016/j.ijantimicag.2017.11.008. Epub 2017 Nov 24.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验